The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
NCT ID: NCT04753385
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
138 participants
OBSERVATIONAL
2021-03-23
2024-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This sub-study is only open to sites participating in the RECOVER clinical study.
All subjects participating in the RECOVER clinical trial at active UNCOVER sites will be offered participation in this sub-study.
Subjects who opt-in to the Mood App portion of the sub-study will be followed for a minimum of 12 months and a maximum of 60 months for the Mood App portion of the sub-study.
Subjects who opt-in to the use of the Study Watch portion of the sub-study will be followed for a minimum of 12 months and maximum of 24 months for the Study Watch portion of the sub-study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Current consented subject in the RECOVER clinical trial;
2. Adult (i.e. ≥ 18 years of age, unless a resident of any U.S. state where the age of majority is 19, in which case must be ≥ 19 years of age);
3. Able and willing to provide written informed consent for this sub-study;
4. Able and willing to comply with all study procedures;
5. Able to read and speak English.
Phone Application
1. Have a personal Google user account or be willing to create and own a personal Google user account;
2. Owns a personal Android smartphone with a data plan and is the sole user of that smartphone;
3. Agrees to download and maintain the phone application onto personal Android smartphone for the duration of the sub-study;
Study Watch
1\. Willing to comply with Study Watch wearing and recharging requirements
Exclusion Criteria
1\. Any condition or situation the Principal Investigator determines as inappropriate for study inclusion
Phone Application
Study Watch
1\. Subjects with known severe allergy to nickel or metal jewelry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LivaNova
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles Conway, MD
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
ATP Clinical Research, Inc.
Costa Mesa, California, United States
Keck Hospital of USC
Los Angeles, California, United States
SF-Care, Inc.
San Rafael, California, United States
Kind Research Group
Boca Raton, Florida, United States
APG Research, LLC
Orlando, Florida, United States
Nova Psychiatry Inc.
Orlando, Florida, United States
Advanced Mental Health Care Inc.
Royal Palm Beach, Florida, United States
Florida Center for TMS
Saint Augustine, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
Augusta University
Augusta, Georgia, United States
AMR-Baber Research, Inc.
Naperville, Illinois, United States
Psychiatric Medicine Associates, LLC
Skokie, Illinois, United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Beacon Medical Group Behavioral Health
South Bend, Indiana, United States
Sheppard Pratt Health Systems
Baltimore, Maryland, United States
Michigan Clinical Research Institute PC
Ann Arbor, Michigan, United States
Psychiatric Care and Research
O'Fallon, Missouri, United States
PsychCare Consultants Research
St Louis, Missouri, United States
Alivation Research, LLC
Lincoln, Nebraska, United States
Hapworth Research Inc.
New York, New York, United States
Center for Neuropsychiatry and Brain Stimulation (CNBS)
Cary, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
OU-SOCM Dept of Psychiatry
Tulsa, Oklahoma, United States
Scranton Medical Institutes
Moosic, Pennsylvania, United States
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, United States
UT Health Austin
Austin, Texas, United States
UT Center of Excellence on Mood Disorders
Houston, Texas, United States
North Pointe Psychiatry
Lewisville, Texas, United States
Neuropsychiatric Associates, Plc
Woodstock, Vermont, United States
Carilion Clinic
Roanoke, Virginia, United States
Seattle Neuropsychiatric Treatment Center
Bellevue, Washington, United States
Center for Anxiety and Depression
Mercer Island, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LND300
Identifier Type: -
Identifier Source: org_study_id